Amneal announces FDA approval and Amneal Pharmaceuticals stock matches its EUR 18.05 prior close

Published on 10/07/2026 at 08:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The average target is USD 22.71. Amneal Pharmaceuticals stock trades EUR 18.05 on October 7, 2026 versus EUR 18.05.

AMRX, US03168L1052, Illustration mit AI erstellt.

Amneal Pharmaceuticals (ISIN US03168L1052) was trading at EUR 18.05 at Lang & Schwarz on October 7, 2026 at 8:16 a.m. CEST, matching the EUR 18.05 prior close. The company announced U.S. Food and Drug Administration approval for its lanreotide injection on September 18, 2026, according to MarketScreener.

Lanreotide adds a new product catalyst

The approved product is a 120 mg/0.5 mL prefilled syringe intended as a generic reference to Somatuline Depot, and the company said it would launch immediately. The approval also carried competitive generic therapy designation, giving Amneal another specialty product milestone alongside its established portfolio.

Amneal's second-quarter 2026 revenue reached USD 796.20 million, up 9.90 percent from USD 724.50 million in the second quarter of 2025. Net income rose to USD 57.66 million from USD 22.40 million, while diluted earnings per share increased to USD 0.18 from USD 0.07, according to Yahoo Finance.

Guidance and analyst valuation diverge

For full-year 2026, Amneal raised its revenue outlook to USD 3.10 billion-USD 3.20 billion from USD 3.05 billion-USD 3.15 billion, as reported by MarketScreener. The higher range places the midpoint at USD 3.15 billion, compared with USD 3.10 billion previously, a USD 50.00 million increase.

The average analyst price target stood at USD 22.71 on October 6, 2026, while the consensus rating was Strong Buy from seven analysts, according to StockAnalysis. That target is stated in U.S. dollars and therefore is not directly compared with the Lang & Schwarz euro quote.

Next results date is October 29

StockAnalysis lists October 29, 2026, before market open, as the next estimated earnings date. The primary listing is Nasdaq under ticker AMRX, and the latest finance quote showed a 52-week USD range of USD 9.56 to USD 21.18 and a market capitalization of USD 6.5 billion as of October 6, 2026.

EUR 18.05 holds before Nasdaq opens

Amneal Pharmaceuticals stock was trading at EUR 18.05 at Lang & Schwarz on October 7, 2026 at 8:16 a.m. CEST, plus 0.00 percent versus the EUR 18.05 prior close at Lang & Schwarz on October 6, 2026. The further course of trading is shown by the continuously updated real-time quote of Amneal Pharmaceuticals stock.